These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39122631)

  • 1. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse models for Aicardi-Goutières syndrome provide clues to the molecular pathogenesis of systemic autoimmunity.
    Behrendt R; Roers A
    Clin Exp Immunol; 2014 Jan; 175(1):9-16. PubMed ID: 23713592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferonopathies in pediatric rheumatology.
    Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferonopathies: a novel set of inborn errors of immunity.
    Crow YJ
    Ann N Y Acad Sci; 2011 Nov; 1238():91-8. PubMed ID: 22129056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling.
    Hansen AL; Buchan GJ; Rühl M; Mukai K; Salvatore SR; Ogawa E; Andersen SD; Iversen MB; Thielke AL; Gunderstofte C; Motwani M; Møller CT; Jakobsen AS; Fitzgerald KA; Roos J; Lin R; Maier TJ; Goldbach-Mansky R; Miner CA; Qian W; Miner JJ; Rigby RE; Rehwinkel J; Jakobsen MR; Arai H; Taguchi T; Schopfer FJ; Olagnier D; Holm CK
    Proc Natl Acad Sci U S A; 2018 Aug; 115(33):E7768-E7775. PubMed ID: 30061387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aicardi-Goutières syndrome and the type I interferonopathies.
    Crow YJ; Manel N
    Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aicardi-Goutières syndrome: a model disease for systemic autoimmunity.
    Lee-Kirsch MA; Wolf C; Günther C
    Clin Exp Immunol; 2014 Jan; 175(1):17-24. PubMed ID: 23786362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Type I Interferonopathies.
    Lee-Kirsch MA
    Annu Rev Med; 2017 Jan; 68():297-315. PubMed ID: 27813875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response.
    Mackenzie KJ; Carroll P; Lettice L; Tarnauskaitė Ž; Reddy K; Dix F; Revuelta A; Abbondati E; Rigby RE; Rabe B; Kilanowski F; Grimes G; Fluteau A; Devenney PS; Hill RE; Reijns MA; Jackson AP
    EMBO J; 2016 Apr; 35(8):831-44. PubMed ID: 26903602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING palmitoylation as a therapeutic target.
    Hansen AL; Mukai K; Schopfer FJ; Taguchi T; Holm CK
    Cell Mol Immunol; 2019 Mar; 16(3):236-241. PubMed ID: 30796349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient.
    Olivieri I; Cattalini M; Tonduti D; La Piana R; Uggetti C; Galli J; Meini A; Tincani A; Moratto D; Fazzi E; Balottin U; Orcesi S
    Lupus; 2013 Sep; 22(10):1064-9. PubMed ID: 23918923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies in Aicardi-Goutières syndrome.
    Crow YJ; Vanderver A; Orcesi S; Kuijpers TW; Rice GI
    Clin Exp Immunol; 2014 Jan; 175(1):1-8. PubMed ID: 23607857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
    Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
    Front Immunol; 2022; 13():825367. PubMed ID: 35418997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.